R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE® Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.
“Clinical development of our bioresorbable sirolimus-eluting scaffold for treating peripheral arterial disease (PAD) is proceeding ahead of schedule and achieving outstanding procedural results,” said Kamal Ramzipoor, CEO of R3 Vascular.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE® Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.
The R3 Vascular platform incorporates an innovative scaffold design and bioresorbable polymer technology resulting in biomechanical performance comparable to metallic stents. The MAGNITUDE BRS, specifically designed to balance mechanical strength and flexibility uses a novel bioresorbable polymer that provides the structural support needed in this complex vascular territory. At a 98-micron strut thickness across all its usable range of diameters, the MAGNITUDE BRS device is the thinnest BRS ever tested in this clinical setting.
“Given the dire and unmet clinical need of patients presenting with CLI undergoing BTK revascularization, we are extremely pleased by the rapid progression of our program,” said R3 Vascular CEO Kamal Ramzipoor. “Our MAGNITUDE BRS is well-positioned to improve the clinical outcomes of these patients by providing temporary mechanical support and sustained drug delivery while reducing the well-established complications associated with permanent implants.”
“In this early clinical experience, we successfully tested the deliverability and mechanical performance of the MAGNITUDE BRS. Post-procedural angiographic and duplex ultrasound data confirms the mechanical properties and ‘stent-like’ results of the MAGNITUDE BRS device in presence of a high-disease burden. We are looking forward to expanding the patient population cohort and following the clinical results over time,” said Dr. Marianne Brodman, Professor and Head, Clinical Division of Medical University of Graz, Austria.
Dr. Juan F. Granada, a strategic advisor to R3 Vascular, added: “In BTK intervention, the prevention of vessel recoil following balloon dilatation is key to prevent negative remodeling and maintain vessel patency over time. BRS offer the best of both worlds by providing vessel support while it is needed and allowing the opportunity for future re-interventions, which is important in this type of patients. The successful validation of this technology may finally offer an effective and durable way to treat patients with this complex medical condition.”.
About R3 Vascular Inc.
R3 Vascular is a privately held, early-stage medical device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds with a sirolimus coating for treatment of PAD below the knee. The R3 Vascular platform combines the best of both worlds of below-the-knee (BTK) therapy, designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals. R3 Vascular is headquartered in Mountain View, Calif., USA, with additional operations in Munich, Germany.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005854/en/
Source: R3 Vascular Inc.
View this news release online at:
http://www.businesswire.com/news/home/20210902005854/en
